Arteriovenous grafts are traditionally used to facilitate hemodialysis. We have re-engineered the arteriovenous graft concept to support transplantation of cells and organoids. The AVGRx is a modified arteriovenous graft that takes advantage of the system’s arterial inflow, venous outflow, capacity for direct blood sensing, and access to blood nutrients and glucose to support allograft survival and function. Our technology has demonstrated the ability to support cellular transplantation without the need for host immunosuppression – which is typically one of the major drawbacks in organ transplantation. Ongoing work is helping determine whether the AVGRx platform can help cure chronic metabolic conditions.